GSK India
- In India, GSK is one of the market leaders with a turnover of Rs. 1500 crore and a share of 6.2 per cent [source: IMS Indian Purchase Audit (IIPA), August 2007]
- GSK leads in several therapeutic segments - dermatology, anti-parasitics, hormones, and anti-infectives (source: IIPA, August 2007)
- GSK has six products in the top 50 brands, and the top five GSK products are Augmentin, Zinetac, Calpol, Phexin, and Betnesol (source: IIPA, August 2007)
- GSK’s vaccines division is ranked first in a fast-growing vaccines market. Some leading products in India are Havrix, Varilrix, Hiberix, Engerix B and Tritanrix (source: IIPA, August 2007)
- GSK India’s R&D centres at Thane and Nashik have been granted recognition by the Department of Scientific and Industrial Research, Government of India
- The number of clinical studies conducted in India is rapidly growing across a range of therapy areas
- GSK India’s social responsibility programmes focus on development of under developed villages, women and children , specifically in the areas of healthcare and education
Learn about asthma
Asthma is one of the most common lung problems in children, with about one in 10 children suffering at some point during childhood. It is less prevalent in adults, although it can develop in later life. The number of people suffering with asthma has increased in recent years. Many believe increasing levels of air pollution is partially to blame
This section may contains information in several formats:
To download PDF files you will need Adobe Reader. If you do not have it installed, it is available free from the Adobe website. PDF links on this site open in a new window.
For audio-visual content you can use either Windows Media Player or Real Player, which can be installed free from their respective websites.